Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 69

1.

Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.

Mujica-Mota R, Varley-Campbell J, Tikhonova I, Cooper C, Griffin E, Haasova M, Peters J, Lucherini S, Talens-Bou J, Long L, Sherriff D, Napier M, Ramage J, Hoyle M.

Health Technol Assess. 2018 Sep;22(49):1-326. doi: 10.3310/hta22490.

2.

Cardiac Toxicity in a Patient Receiving Peptide Receptor Radionuclide Therapy.

Hendifar AE, Delpassand ES, Kittleson MM, Tuli R.

Pancreas. 2018 Sep;47(8):e55-e56. doi: 10.1097/MPA.0000000000001101. No abstract available.

PMID:
30113434
3.

Peptide receptor radionuclide therapy with 177Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review.

Magalhães D, Sampaio IL, Ferreira G, Bogalho P, Martins-Branco D, Santos R, Duarte H.

J Endocrinol Invest. 2019 Mar;42(3):249-260. doi: 10.1007/s40618-018-0911-3. Epub 2018 Jun 9. Review.

PMID:
29949120
4.

Response to Single Low-dose 177Lu-DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm: A Prospective Pilot Study.

Wang H, Cheng Y, Zhang J, Zang J, Li H, Liu Q, Wang J, Jacobson O, Li F, Zhu Z, Chen X.

Theranostics. 2018 May 12;8(12):3308-3316. doi: 10.7150/thno.25919. eCollection 2018.

5.

177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.

Demirci E, Kabasakal L, Toklu T, Ocak M, Şahin OE, Alan-Selcuk N, Araman A.

Nucl Med Commun. 2018 Aug;39(8):789-796. doi: 10.1097/MNM.0000000000000874.

PMID:
29912750
6.

Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial).

Braat AJAT, Kwekkeboom DJ, Kam BLR, Teunissen JJM, de Herder WW, Dreijerink KMA, van Rooij R, Krijger GC, de Jong HWAM, van den Bosch MAAJ, Lam MGEH.

BMC Gastroenterol. 2018 Jun 15;18(1):84. doi: 10.1186/s12876-018-0817-8.

7.

The human somatostatin receptor type 2 as an imaging and suicide reporter gene for pluripotent stem cell-derived therapy of myocardial infarction.

Neyrinck K, Breuls N, Holvoet B, Oosterlinck W, Wolfs E, Vanbilloen H, Gheysens O, Duelen R, Gsell W, Lambrichts I, Himmelreich U, Verfaillie CM, Sampaolesi M, Deroose CM.

Theranostics. 2018 Apr 14;8(10):2799-2813. doi: 10.7150/thno.22980. eCollection 2018.

8.

Acute Pancreatitis Following Peptide Receptor Radionuclide Therapy: An Unusual Adverse Event.

Karfis I, Marin G, Machiels G, Hendlisz A, Flamen P.

Clin Nucl Med. 2018 Jul;43(7):e232-e233. doi: 10.1097/RLU.0000000000002118.

PMID:
29762236
9.

Segmentation of Whole-Body Images into Two Compartments in Model for Bone Marrow Dosimetry Increases the Correlation with Hematological Response in 177Lu-DOTATATE Treatments.

Hagmarker L, Svensson J, Rydén T, Gjertsson P, Bernhardt P.

Cancer Biother Radiopharm. 2017 Nov;32(9):335-343. doi: 10.1089/cbr.2017.2317. Epub 2017 Nov 10.

PMID:
29125780
10.

Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients With Advanced Neuroendocrine Tumors: A Long-term-Outcome, Toxicity, Survival, and Quality-of-Life Study.

Ballal S, Yadav MP, Damle NA, Sahoo RK, Bal C.

Clin Nucl Med. 2017 Nov;42(11):e457-e466. doi: 10.1097/RLU.0000000000001816.

PMID:
28872545
11.

Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30.

Marinova M, Mücke M, Mahlberg L, Essler M, Cuhls H, Radbruch L, Conrad R, Ahmadzadehfar H.

Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):38-46. doi: 10.1007/s00259-017-3816-z. Epub 2017 Sep 1.

PMID:
28864881
12.

Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.

Hamiditabar M, Ali M, Bolek L, Vahdati G, Tworowska I, Delpassand ES.

Clin Nucl Med. 2017 Nov;42(11):822-828. doi: 10.1097/RLU.0000000000001818.

PMID:
28832377
13.

Peptide Receptor Radionuclide Therapy-Induced Gitelman-like Syndrome.

Negro A, Rossi GM, Nicoli D, Versari A, Farnetti E, Santi R, De Pietri S.

Am J Kidney Dis. 2017 Nov;70(5):725-728. doi: 10.1053/j.ajkd.2017.05.024. Epub 2017 Jul 21.

PMID:
28739329
14.

Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.

Cheal SM, Fung EK, Patel M, Xu H, Guo HF, Zanzonico PB, Monette S, Wittrup KD, Cheung NV, Larson SM.

J Nucl Med. 2017 Nov;58(11):1735-1742. doi: 10.2967/jnumed.117.193250. Epub 2017 Jul 13.

15.

Early efficacy of and toxicity from lutetium-177-DOTATATE treatment in patients with progressive metastatic NET.

Pencharz D, Walker M, Yalchin M, Quigley AM, Caplin M, Toumpanakis C, Navalkissoor S.

Nucl Med Commun. 2017 Jul;38(7):593-600. doi: 10.1097/MNM.0000000000000685.

PMID:
28471845
16.

Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors.

Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, van Eijck CHJ, Franssen GJH, Krenning EP, Kwekkeboom DJ.

Clin Cancer Res. 2017 Aug 15;23(16):4617-4624. doi: 10.1158/1078-0432.CCR-16-2743. Epub 2017 Apr 20.

17.

Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study.

Kunikowska J, Pawlak D, Bąk MI, Kos-Kudła B, Mikołajczak R, Królicki L.

Ann Nucl Med. 2017 Jun;31(5):347-356. doi: 10.1007/s12149-017-1163-6. Epub 2017 Mar 18.

PMID:
28316066
18.

Treatment with 177Lu-DOTATATE: Past, present and future.

Estorch M.

Rev Esp Med Nucl Imagen Mol. 2017 Mar - Apr;36(2):69-71. doi: 10.1016/j.remn.2017.01.009. English, Spanish. No abstract available.

PMID:
28257748
19.

177Lu-Dotatate for midgut neuroendocrine tumours.

Burki TK.

Lancet Oncol. 2017 Feb;18(2):e74. doi: 10.1016/S1470-2045(17)30042-6. Epub 2017 Jan 20. No abstract available.

PMID:
28111117
20.

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.

Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators.

N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.

Supplemental Content

Loading ...
Support Center